Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
HOME > REGULATORY
REGULATORY
- Restrictions on Continuous Psychotropic Use Up for Chuikyo Discussions
October 19, 2017
- Price Maintenance Premium, Z2 Reduction Rates under Attack by CEFP Working Group
October 19, 2017
- Chuikyo Discussing Measures to Promote Proper Use of Clozaril for Patients with Treatment-Resistant Schizophrenia
October 19, 2017
- National Database Initiative for Regenerative Medicine Goes Live; Use for Review, Development Eyed
October 18, 2017
- Label Revisions Ordered for 5 APIs, Hitting Slew of Amoxicillin/Chlorhexidine Products
October 18, 2017
- Post-Transplant Patients Added to Careful Use List for Keytruda Label/Guidelines
October 18, 2017
- MHLW to Issue Notification on Revised Format for Package Inserts of Vaccines in Early December
October 18, 2017
- Cabinet Secretariat to Discuss Details of Research on Genome Editing to Be Supported by AMED
October 16, 2017
- MHLW to Purchase Enough Avigan for 44,000 More People, Agreement Expected Nov. 1
October 13, 2017
- Pricing Predictability Could Crumble via Japanese CEA Introduction, Tada Frets at Chuikyo
October 12, 2017
- Premium Rate Threshold Could Preclude CEA-Based Price Raise for Inapplicable Products: Chuikyo Doctor Rep
October 12, 2017
- FPMAJ Chief Trades Barbs with Chuikyo Payer Rep, Says Western-Style HTA Doesn’t Fit Japan’s Unique Market Mechanism
October 12, 2017
- Claims to ADR Victims Relief System Up 277 in FY2016: MHLW
October 12, 2017
- Any CEA-Based Price Adjustment Must Be Limited to Premium Rates: 3 Pharma Groups
October 11, 2017
- MHLW to Issue Basic Guide to PMS for Conditional Early Approval: Drug Review Chief
October 11, 2017
- Japan Needs “Quick and Low-Cost” R&D Setup: Top MD Bureaucrat
October 10, 2017
- MHLW’s JETRO NY Post Ended Because There Was No Request: Govt
October 10, 2017
- Health Minister Questions How to Gauge Success in Outcome-Based CAR-T Pricing in Japan
October 10, 2017
- Revised Ministerial Ordinance on Preventing Distribution of Counterfeit Drugs to Take Effect Jan. 31
October 10, 2017
- 3rd Round of Sakigake Invitations Begin
October 6, 2017
ページ
Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…